1. Home
  2. KMB vs INSM Comparison

KMB vs INSM Comparison

Compare KMB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimberly-Clark Corporation

KMB

Kimberly-Clark Corporation

HOLD

Current Price

$95.37

Market Cap

32.3B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$139.89

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMB
INSM
Founded
1910
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3B
30.1B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
KMB
INSM
Price
$95.37
$139.89
Analyst Decision
Hold
Strong Buy
Analyst Count
13
24
Target Price
$113.54
$201.17
AVG Volume (30 Days)
4.5M
1.6M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
5.33%
N/A
EPS Growth
N/A
N/A
EPS
2.00
N/A
Revenue
$16,447,000,000.00
N/A
Revenue This Year
$3.83
$182.31
Revenue Next Year
$3.61
$65.19
P/E Ratio
$48.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$92.42
$63.81
52 Week High
$144.31
$212.75

Technical Indicators

Market Signals
Indicator
KMB
INSM
Relative Strength Index (RSI) 41.50 44.60
Support Level $92.42 $136.24
Resistance Level $100.41 $166.81
Average True Range (ATR) 2.10 4.93
MACD 0.09 -0.86
Stochastic Oscillator 7.74 32.81

Price Performance

Historical Comparison
KMB
INSM

About KMB Kimberly-Clark Corporation

With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: